![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
Myovant grants Pfizer sublicense option on relugolix and RVT602
Executive Summary
Under a deal concurrent with the closing of its $202mm initial public offering, Myovant Sciences Ltd. granted an affiliate of Pfizer Inc. the right of first negotiation (ROFN) to a sublicense to two male and female health drug candidates Myovant previously in-licensed from Takeda Pharmaceutical.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice